Antibody generated through a partnership between ReceptaBio, LCR and the company 4-Antibody (which was later acquired by Agenus Inc.). It is a human monoclonal antibody to block the programmed death 1 (PD-1) cell protein, an important negative regulator (suppressor) of T lymphocyte responses. By blocking PD-1, the immune response is increased through the inhibition of negative regulation of T lymphocytes activation, consequently increasing the antitumor immune response. Using data from the Phase I clinical studies, being conducted in the United States (NCT03104699), the dose for an ongoing Phase II clinical study on cervical cancer was defined. This molecule is also in a Phase I clinical study in combination with RebmAb600/AGEN1884 (NCT03495882). By acting increasing the response of the immune system to the tumor, studies are planned in several therapeutic indications for RebmAb700.